Biologics for chronic rhinosinusitis.

@article{Chong2021BiologicsFC,
  title={Biologics for chronic rhinosinusitis.},
  author={Lee Yee Chong and Patorn Piromchai and Steve Sharp and Kornkiat Snidvongs and Katie E. Webster and Carl Martin Philpott and Claire Hopkins and Martin J. Burton},
  journal={The Cochrane database of systematic reviews},
  year={2021},
  volume={3},
  pages={
          CD013513
        }
}
BACKGROUND This living systematic review is one of several Cochrane Reviews evaluating the medical management of patients with chronic rhinosinusitis. Chronic rhinosinusitis is common. It is characterised by inflammation of the nasal and sinus linings, nasal blockage, rhinorrhoea, facial pressure/pain and loss of sense of smell. It occurs with or without nasal polyps.   'Biologics' are medicinal products produced by a biological process. Monoclonal antibodies are one type, already evaluated in… 

Pharmacological, Technological, and Digital Innovative Aspects in Rhinology

Supporting the research of innovative tools and strategies (including pharmacological, technologic, or digital ones) is essential to improve the management of chronic diseases that significantly affect the patients' quality of life.

References

SHOWING 1-10 OF 136 REFERENCES

Biologics for chronic rhinosinusitis.

This living systematic review is one of several Cochrane Reviews evaluating the medical management of patients with chronic rhinosinusitis and three biologics, with different targets, were evaluated: dupilumab, mepolizumAB and omalizumab.

Different types of intranasal steroids for chronic rhinosinusitis.

Low quality evidence was found relating to disease severity and nasal polyps size, with results from the high-dose and low-dose groups being similar and the primary adverse effect, epistaxis, was more common when higher doses were used.

Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis.

The effects of intranasal corticosteroids in people with chronic rhinosinusitis were assessed, disease-specific health-related quality of life (HRQL), patient-reported disease severity and the commonest adverse event - epistaxis.

Short-course oral steroids alone for chronic rhinosinusitis.

The results at the end of treatment showed an improvement in patients receiving oral steroids compared to placebo, both when presented as a mean final value and as a change from baseline, which corresponds to a large effect size.

Topical and systemic antifungal therapy for chronic rhinosinusitis.

The main outcomes were disease-specific health-related quality of life, patient-reported disease severity and the significant adverse effects of hepatic toxicity (systemic antifungals), and the quality of the evidence for each outcome.

Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis.

A short course of oral corticosteroids as an adjunct ('add-on') therapy in people with chronic rhinosinusitis who are already on standard treatments and there was a greater improvement in symptom severity 30 days after the start of treatment in patients who received oral steroids and antibiotics.

Saline irrigation for chronic rhinosinusitis.

The effects of saline irrigation in patients with chronic rhinosinusitis was evaluated and the evidence was assessed to be of low quality for the three months follow-up and very lowquality for the six months following-up.

Biologics in Chronic Rhinosinusitis with Nasal Polyposis.

  • T. LaidlawK. Buchheit
  • Medicine, Biology
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2019

The role of biologics in chronic rhinosinusitis: a systematic review

The role of monoclonal antibodies (MAbs) in the treatment of CRS with polyps and without polyps is identified, especially with regard to comparability with current medical treatment, efficacy, and risk of complications.

Anti-IgE monoclonal antibody therapy for the treatment of chronic rhinosinusitis: a systematic review

There is currently insufficient evidence to determine the effectiveness of anti-IgE monoclonal antibody therapy for the treatment of CRS.
...